[{"data":1,"prerenderedAt":164},["ShallowReactive",2],{"drug-cangrelor":3},{"id":4,"schemaVersion":5,"name":6,"category":9,"class":10,"brands":13,"synonyms":17,"formulations":19,"regimens":33,"contraindications":72,"warnings":82,"renal":83,"monitoring":84,"interactions":85,"review":86,"examples":89,"atc":102,"iran":104,"usApproval":111,"links":117,"populations":128},"cangrelor",1,{"fa":7,"en":8},"کانگرلور","Cangrelor","blood",{"fa":11,"en":12},"مهارکننده وریدی P2Y12","IV P2Y12 inhibitor",[14],{"name":15,"market":16},"Kengreal","US",[18,7],"kengreal",[20],{"id":21,"form":22,"route":23,"label":24,"concentration":25,"markets":28,"refs":29},"dil-200","injection","iv","50 mg vial diluted in 250 mL (200 mcg\u002FmL)",{"amount":26,"unit":27,"perVolumeMl":5},200,"mcg",[16],[30],{"source":31,"section":32},"fda-kengreal","2.3",[34,52],{"id":35,"disease":36,"label":37,"population":40,"type":44,"unit":27,"dose":45,"refs":48,"durationDays":51},"bolus","acute-coronary-syndrome",{"fa":38,"en":39},"PCI — بولوس ۳۰ mcg\u002Fkg پیش از PCI","PCI — 30 mcg\u002Fkg bolus before PCI",{"minAge":41},{"value":42,"unit":43},18,"year","weightBased",{"perKgPerDose":46,"intervalHours":47},30,24,[49],{"source":31,"section":50},"2.1",{"min":5,"max":5},{"id":53,"disease":36,"label":54,"population":57,"type":59,"unit":27,"dose":60,"refs":62,"notes":64},"inf",{"fa":55,"en":56},"انفوزیون ۴ mcg\u002Fkg\u002Fدقیقه بلافاصله پس از بولوس، دست‌کم ۲ ساعت یا تا پایان PCI","Infusion 4 mcg\u002Fkg\u002Fmin right after the bolus, ≥2 h or the duration of PCI",{"minAge":58},{"value":42,"unit":43},"infusion",{"perKgPerMin":61},4,[63],{"source":31,"section":50},[65],{"text":66,"refs":69},{"fa":67,"en":68},"پس از قطع، P2Y12 خوراکی: تیکاگرلور ۱۸۰ mg حین یا بلافاصله پس از انفوزیون؛ پراسوگرل ۶۰ mg یا کلوپیدوگرل ۶۰۰ mg بلافاصله پس از قطع.","After stopping, oral P2Y12: ticagrelor 180 mg during or right after; prasugrel 60 mg or clopidogrel 600 mg immediately after discontinuation.",[70],{"source":31,"section":71},"2.2",[73],{"id":74,"severity":75,"text":76,"refs":79},"ci","block",{"fa":77,"en":78},"خونریزی فعال قابل‌توجه؛ حساسیت به کانگرلور.","Significant active bleeding; hypersensitivity to cangrelor.",[80],{"source":31,"section":81},"4",[],[],[],[],{"status":87,"reviewer":88,"date":88},"unverified",null,[90,97],{"regimen":35,"formulation":21,"input":91,"expect":94},{"ageYears":92,"weightKg":93},60,70,{"perDose":95,"mlPerDose":96},2100,10.5,{"regimen":53,"formulation":21,"input":98,"expect":99},{"ageYears":92,"weightKg":93},{"perMin":100,"mlPerHour":101},280,84,[103],"B01AC25",{"status":105,"refs":106},"not-found",[107],{"source":108,"section":109,"url":110},"darooyab-generic","search","https:\u002F\u002Fwww.darooyab.ir\u002FSearch?q=Cangrelor",{"kind":112,"refs":113,"id":116},"NDA",[114],{"source":31,"section":115},"SPL approval \u002F marketing category","NDA204958",[118,121,125],{"kind":119,"url":120,"label":116},"fda","https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fcder\u002Fdaf\u002Findex.cfm?event=overview.process&ApplNo=204958",{"kind":122,"url":123,"label":124},"dailymed","https:\u002F\u002Fdailymed.nlm.nih.gov\u002Fdailymed\u002FdrugInfo.cfm?setid=88b434fa-8891-4fd5-9d86-7ea64667c08f","FDA Kengreal",{"kind":126,"url":127,"label":103},"who-atc","https:\u002F\u002Fatcddd.fhi.no\u002Fatc_ddd_index\u002F?code=B01AC25",{"pregnancy":129,"lactation":138,"pediatric":146,"geriatric":155},{"level":130,"text":131,"quote":134,"refs":135},"caution",{"fa":132,"en":133},"برچسب خطر مشخصی برای بارداری ذکر نکرده یا داده کافی ندارد؛ فقط در صورت لزوم و با نظر پزشک.","Label states no clear risk or has limited data; use only if needed, under medical advice.","Risk Summary There are no available data on cangrelor use in pregnant women to evaluate for a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes.",[136],{"source":31,"section":137},"8.1",{"level":130,"text":139,"quote":142,"refs":143},{"fa":140,"en":141},"برچسب: در شیردهی با احتیاط؛ متن برچسب را ببینید.","Label: use with caution while breastfeeding; see the label text.","Risk Summary There are no data on the presence of cangrelor in human milk or animal milk, the effects on the breastfed infant, or the effects on milk production.",[144],{"source":31,"section":145},"8.2",{"level":147,"text":148,"quote":151,"refs":152},"not-established",{"fa":149,"en":150},"برچسب: ایمنی و اثربخشی در کودکان ثابت نشده است.","Label: safety and effectiveness in children have not been established.","Safety and effectiveness in pediatric patients have not been established.",[153],{"source":31,"section":154},"8.4",{"level":156,"text":157,"quote":160,"refs":161},"ok",{"fa":158,"en":159},"برچسب: در سالمندان تفاوت یا تنظیم دوز خاصی ذکر نشده.","Label: no specific difference or dose adjustment stated for older adults.","No overall differences in safety or effectiveness were observed between these patients and those patients \u003C75 years [see Clinical Studies ( 14.1 )] .",[162],{"source":31,"section":163},"8.5",1792191530829]